LYN and cancer: In the pan-cancer analysis, LYN indicated worse OS in thymoma (THYM), uveal melanoma (UVM), uterine carcinosarcoma (UCS), acute myeloid leukemia (LAML), kidney renal papillary cell carcinoma (KIRP), uterine corpus endometrial carcinoma (UCEC), liver hepatocellular carcinoma (LIHC), mesothelioma (MESO), breast invasive carcinoma (BRCA), ovarian serous pancreatic adenocarcinoma (PAAD), and testicular germ cell tumors (TGCT) (Supplementary Figure S4).